Current Concepts of Severe Asthma

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2016 Jul 2

PMID 27367183

Citations 102

Authors

Anuradha Ray

Mahesh Raundhal

Timothy B Oriss

Prabir Ray

Sally E Wenzel

Affiliations

Soon will be listed here.

Abstract

The term asthma encompasses a disease spectrum with mild to very severe disease phenotypes whose traditional common characteristic is reversible airflow limitation. Unlike milder disease, severe asthma is poorly controlled by the current standard of care. Ongoing studies using advanced molecular and immunological tools along with improved clinical classification show that severe asthma does not identify a specific patient phenotype, but rather includes patients with constant medical needs, whose pathobiologic and clinical characteristics vary widely. Accordingly, in recent clinical trials, therapies guided by specific patient characteristics have had better outcomes than previous therapies directed to any subject with a diagnosis of severe asthma. However, there are still significant gaps in our understanding of the full scope of this disease that hinder the development of effective treatments for all severe asthmatics. In this Review, we discuss our current state of knowledge regarding severe asthma, highlighting different molecular and immunological pathways that can be targeted for future therapeutic development.

Citing Articles

Sex hormones and allergies: exploring the gender differences in immune responses.

Gutierrez-Brito J, Lomeli-Nieto J, Munoz-Valle J, Oregon-Romero E, Corona-Angeles J, Hernandez-Bello J Front Allergy. 2025; 5():1483919.

PMID: 39840271 PMC: 11747284. DOI: 10.3389/falgy.2024.1483919.

Dendritic cell-specific deletion of PKCδ in offspring of allergic mothers prevents the predisposition for development of allergic lung inflammation in offspring.

Lajiness J, Bloodworth J, Blankenship R, Kosins A, Cook-Mills J J Leukoc Biol. 2024; 116(6):1432-1445.

PMID: 39312649 PMC: 11599121. DOI: 10.1093/jleuko/qiae207.

Neutralizing Oxidized Phosphatidylcholine Reduces Airway Inflammation and Hyperreactivity in a Murine Model of Allergic Asthma.

Vaghasiya J, Jha A, Basu S, Bagan A, Jengsuksavat S, Ravandi A Biology (Basel). 2024; 13(8).

PMID: 39194564 PMC: 11351608. DOI: 10.3390/biology13080627.

Identification of candidate genes and molecular mechanisms related to asthma progression using bioinformatics.

Zou S, Meng F, Xu G, Yu R, Yang C, Wei Q Sleep Breath. 2024; 28(5):2237-2246.

PMID: 39088141 PMC: 11450000. DOI: 10.1007/s11325-024-03122-0.

CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy.

Mohammad Taheri M, Javan F, Poudineh M, Athari S Clin Rev Allergy Immunol. 2024; 66(3):328-362.

PMID: 38995478 DOI: 10.1007/s12016-024-08998-0.

References

Ordonez C, Shaughnessy T, Matthay M, Fahy J . Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: Clinical and biologic significance. Am J Respir Crit Care Med. 2000; 161(4 Pt 1):1185-90. DOI: 10.1164/ajrccm.161.4.9812061. View

Stirling R, Kharitonov S, Campbell D, Robinson D, Durham S, Chung K . Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids. Asthma and Allergy Group. Thorax. 1999; 53(12):1030-4. PMC: 1745124. DOI: 10.1136/thx.53.12.1030. View

Lazear H, Daniels B, Pinto A, Huang A, Vick S, Doyle S . Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier. Sci Transl Med. 2015; 7(284):284ra59. PMC: 4435724. DOI: 10.1126/scitranslmed.aaa4304. View

Burdette D, Monroe K, Sotelo-Troha K, Iwig J, Eckert B, Hyodo M . STING is a direct innate immune sensor of cyclic di-GMP. Nature. 2011; 478(7370):515-8. PMC: 3203314. DOI: 10.1038/nature10429. View

Yu M, Eckart M, Morgan A, Mukai K, Butte A, Tsai M . Identification of an IFN-γ/mast cell axis in a mouse model of chronic asthma. J Clin Invest. 2011; 121(8):3133-43. PMC: 3148724. DOI: 10.1172/JCI43598. View

Wang J, Palmer K, Lotvall J, Milan S, Lei X, Matthaei K . Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia. J Clin Invest. 1998; 102(6):1132-41. PMC: 509096. DOI: 10.1172/JCI2686. View

Barrios V, Jarosinski M, Wright C . Proteinase-activated receptor-2 mediates hyperresponsiveness in isolated guinea pig bronchi. Biochem Pharmacol. 2003; 66(3):519-25. DOI: 10.1016/s0006-2952(03)00292-2. View

Fleming L, Murray C, Bansal A, Hashimoto S, Bisgaard H, Bush A . The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J. 2015; 46(5):1322-33. DOI: 10.1183/13993003.00780-2015. View

Bachert C, Gevaert P, Holtappels G, JOHANSSON S, Van Cauwenberge P . Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol. 2001; 107(4):607-14. DOI: 10.1067/mai.2001.112374. View

10.

Moore W, Bleecker E, Curran-Everett D, Erzurum S, Ameredes B, Bacharier L . Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. 2007; 119(2):405-13. PMC: 2837934. DOI: 10.1016/j.jaci.2006.11.639. View

11.

Nakamura Y, Ghaffar O, Olivenstein R, Taha R, Zhang D, Ray A . Gene expression of the GATA-3 transcription factor is increased in atopic asthma. J Allergy Clin Immunol. 1999; 103(2 Pt 1):215-22. DOI: 10.1016/s0091-6749(99)70493-8. View

12.

Krug N, Hohlfeld J, Kirsten A, Kornmann O, Beeh K, Kappeler D . Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med. 2015; 372(21):1987-95. DOI: 10.1056/NEJMoa1411776. View

13.

Guo F, Uetani K, Haque S, Williams B, Dweik R, Thunnissen F . Interferon gamma and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. J Clin Invest. 1997; 100(4):829-38. PMC: 508255. DOI: 10.1172/JCI119598. View

14.

Busse W, Holgate S, Kerwin E, Chon Y, Feng J, Lin J . Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013; 188(11):1294-302. DOI: 10.1164/rccm.201212-2318OC. View

15.

Stirling R, van Rensen E, Barnes P, Chung K . Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. Am J Respir Crit Care Med. 2001; 164(8 Pt 1):1403-9. DOI: 10.1164/ajrccm.164.8.2010002. View

16.

Reddy A, Gupta M . Management of asthma: the current US and European guidelines. Adv Exp Med Biol. 2013; 795:81-103. DOI: 10.1007/978-1-4614-8603-9_6. View

17.

Castro M, Mathur S, Hargreave F, Boulet L, Xie F, Young J . Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184(10):1125-32. DOI: 10.1164/rccm.201103-0396OC. View

18.

Castro M, Wenzel S, Bleecker E, Pizzichini E, Kuna P, Busse W . Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014; 2(11):879-890. DOI: 10.1016/S2213-2600(14)70201-2. View

19.

Ray A, Oriss T, Wenzel S . Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol. 2014; 308(2):L130-40. PMC: 4338947. DOI: 10.1152/ajplung.00070.2014. View

20.

Gauvreau G, OByrne P, Boulet L, Wang Y, Cockcroft D, Bigler J . Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014; 370(22):2102-10. DOI: 10.1056/NEJMoa1402895. View